Market: NMS |
Currency: USD
Address: 43 Thorndike Street
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
📈 Amylyx Pharmaceuticals, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$22.80
-
Upside/Downside from Analyst Target:
44.67%
-
Broker Call:
21
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
50-100%
-
Revenue Growth Range (1Y):
<0%
-
Upcoming Earnings Date:
2026-05-07
-
EPS Estimate:
-0.36
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Amylyx Pharmaceuticals, Inc.
| Date | Reported EPS |
|---|
| 2026-05-07 (estimated upcoming) | - |
| 2026-03-03 | -0.3 |
| 2025-11-06 | -0.37 |
| 2025-08-07 | -0.46 |
| 2025-05-08 | -0.42 |
| 2025-03-04 | -0.55 |
| 2024-11-07 | -1.07 |
| 2024-08-08 | -0.62 |
| 2024-05-09 | -0.12 |
| 2024-02-22 | 0.07 |
| 2023-11-09 | 0.3 |
| 2023-08-10 | 0.31 |
| 2023-05-11 | 0.02 |
| 2023-03-13 | -0.65 |
| 2022-11-10 | -0.92 |
| 2022-08-11 | -0.93 |
| 2022-05-12 | -0.93 |
| 2022-03-31 | -4.15 |
📰 Related News & Research
-
Amylyx Pharmaceuticals Advances Novel Therapies for Rare Diseases: Avexitide, AMX0035, and AMX0114 Show Promise in Clinical Trials for PBH, Wolfram Syndrome, and ALS
March 24, 2026
Amylyx Pharmaceuticals: Key Pipeline Updates, Clinical Miles...
-
Amylyx Pharmaceuticals Announces 2025 Financial Results, Phase 3 Avexitide Progress, and 2026 Milestones for PBH and ALS Programs
March 3, 2026
Amylyx Pharmaceuticals Q4 & FY2025 Financial Results: Key Hi...
-
Amylyx Pharmaceuticals 2025 Annual Report: Clinical Pipeline, Business Overview, Regulatory, and Intellectual Property Insights
March 3, 2026
Amylyx Pharmaceuticals, Inc. 2025 Annual Report: Key Highlig...
🔍 View more Reports
